Developer docs
API playgroundTry for free, no card

Search company profiles

Lucid Group

Full company profile

uuid000bysr

Namestring
Lucid Group
Legal namestring
Lucid Group Communications Limited
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Lucid Group is a London-headquartered strategic healthcare communications consultancy founded in 2007, serving pharmaceutical, biotechnology, medical device, and consumer healthcare companies. The firm delivers an integrated portfolio spanning strategy consulting, scientific and medical communications, commercial communications, and digital/creative services, with approximately 500-600 specialists operating from four offices in the UK (London, Macclesfield, Manchester) and the US (Philadelphia). The company is privately held and backed by alternative asset manager Intermediate Capital Group (ICG), with founder Dennis O'Brien continuing as CEO and former Pfizer R&D leader Rod MacKenzie appointed Board Chair in 2026.

At the core of Lucid's offering is the proprietary Lucid Connected Intelligence (LCI) platform, which mines millions of patient healthcare interaction data points spanning diagnosis, prescription, procedure, demographic, and geographic information to support market definition, journey mapping, HCP behavior analysis, and campaign optimisation. AI-enabled solutions are positioned as 'woven in by design' across the asset lifecycle, supporting strategy refinement, content generation, and omnichannel activation. Lucid reports a 20+ year track record with 100+ product launches delivered across high-science therapeutic areas, with documented outcomes including 168% of sales target achievement for an oncology launch, 9x audience growth with doubled ROI to 5.6:1 for a multiple sclerosis brand, and 63% oncologist brand recognition within six months of launch.

Lucid monetises through project-based professional services engagements and retainer arrangements with enterprise life sciences clients, building bespoke teams per engagement. The firm has expanded through inorganic moves including the 2019 acquisition of HealthCare21, the 2021 acquisition of US-based DiD (strategic brand consultancy), and the 2023 acquisition of Synetic Life Sciences (life sciences management consulting). Lucid holds ISO 27001 certification (2025), EcoVadis Silver status placing it in the top 25% of rated companies, and United Nations Global Compact membership, signalling enterprise-grade security and ESG maturity valued by global pharma procurement.

Short descriptiontext

Lucid Group is a London-headquartered healthcare communications consultancy serving pharmaceutical, biotech, MedTech, and consumer health clients with strategy consulting, medical communications, and AI-enabled analytics across UK and US offices.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare communications, pharmaceutical consulting, medical communications services, life sciences strategy, brand commercialisation consulting
Industry1 code
PRIMARYMPAAADAD
Healthcare & Life Sciences PR
Media, Entertainment & Sports/Advertising, Marketing & PR Services/Public Relations & Communications Agencies
NAICS code3 codes
  • Advertising, Public Relations, and Related Services5418
  • Management Consulting Services54161
  • Marketing Consulting Services541613
SIC code1 code
  • Services-Management Consulting Services8742
Product category
Healthcare Communications Consulting
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic Consulting Services
TypeProfessional Services
Description

Strategy consulting engagements for life sciences including clinical development, medical affairs, asset commercialisation, and HCP/patient engagement

wearelucidgroup.com:443
2Scientific and Medical Communications
TypeProfessional Services
Description

Strategic scientific and medical communications services with deep scientific and therapy area expertise supporting Global and US markets

wearelucidgroup.com:443
3Commercial Communications
TypeProfessional Services
Description

Commercial communications services including omnichannel programmes, creative development, and brand strategy execution

wearelucidgroup.com:443
4Digital and Creative Services
TypeProfessional Services
Description

Digital and creative consultancy services integrated with strategic communications for end-to-end healthcare marketing solutions

wearelucidgroup.com:443
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Project-based consulting engagements for life sciences organisations
ModelOther
Notes

Consulting services scoped and priced based on project complexity, team requirements, and engagement duration. No public pricing tiers available.

wearelucidgroup.com:443
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1Lucid Connected Intelligence (LCI)
Description

Proprietary business intelligence engine that mines patient healthcare interaction data for analytics and targeting

wearelucidgroup.com:443
+4 more records
Core offering1 text field

Lucid Group is a global healthcare communications consultancy that helps pharmaceutical, biotech, and life sciences companies translate scientific evidence into stakeholder belief and commercial outcomes across the asset lifecycle. Its portfolio includes Strategy Consulting, Scientific and Medical Communications, Commercial Communications, and proprietary analytics through the Lucid Connected Intelligence (LCI) platform, supported by AI-Powered Solutions and acquired capabilities from DiD Agency and Synetic Life Sciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 168% of product sales target met within 6 months of launch for first systemic therapy in specialised oncology
+4 more records
Product overview1 text field

Lucid Group is a global strategic healthcare communications consultancy offering an integrated portfolio of services. The core offering comprises Strategy Consulting (strategic solutions for life sciences spanning clinical development, medical affairs, and commercialisation), Scientific and Medical Communications (translating scientific insight into impactful narratives), Commercial Communications (omnichannel programmes and creative development), and AI-Powered Solutions (AI-enabled tools woven throughout all services). The proprietary Lucid Connected Intelligence (LCI) platform serves as the analytics engine powering data-driven insights across the portfolio. The company has expanded through strategic acquisitions including DiD Agency (US-based strategic brand consultancy with customer-centric marketing expertise) and Synetic Life Sciences (life sciences management consulting for operating model design and implementation).

Product and service7 records
1Strategy Consulting
CategoryStrategy Consulting
Description

Strategic consulting services for life sciences organisations spanning clinical development, medical affairs, asset commercialisation, and HCP/patient engagement, using data- and science-based approaches to help clients set direction and transform ideas into action across the product lifecycle.

2Scientific and Medical Communications
CategoryMedical Communications
Description

Strategic scientific and medical communications services with deep therapy-area expertise supporting global and US markets, translating scientific insight into impactful strategies and compelling narratives that inspire behaviour change among HCPs and other stakeholders.

3Commercial Communications
CategoryCommercial Communications
Description

Commercial communications services including omnichannel programmes, creative development, media planning and activation, and digital content designed to drive clinical change, champion early adopters, and grow brand awareness for healthcare clients.

4Lucid Connected Intelligence (LCI)
CategoryAnalytics Platform
Description

Proprietary advanced analytics platform that mines patient healthcare interaction data — including diagnosis, prescription, procedure, demographic, and geographic data — to identify patterns in patient populations, HCP behaviours, and market dynamics, enabling data-driven targeting, segmentation, and campaign optimisation for healthcare brands.

5AI-Powered Solutions
CategoryAI-Enabled Services
Description

AI-enabled solutions integrated with human insight, therapeutic depth, and behaviour-change expertise to amplify insight, accelerate execution, sharpen strategy, and drive lasting impact across the asset lifecycle.

6DiD Agency
CategoryStrategic Brand Consultancy
Description

US-based strategic brand consultancy specialising in customer-centric marketing for life sciences, offering the 3-30/3-30 engagement framework for healthcare communications with expertise in market research, strategic insight development, and creative execution.

7Synetic Life Sciences
CategoryManagement Consulting
Description

Management consulting firm dedicated to life sciences, offering operating model design and implementation, strategic process and capability development, and support for planning and execution across the asset lifecycle.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-18
Description

Lucid Group acquired Synetic Life Sciences, a management consulting firm dedicated to the life sciences industry. The acquisition provides clients with an end-to-end partnership across the development and commercialisation journey. Synetic supports clients with the design and implementation of operating models including building effective strategies, processes, capabilities, and organisational constructs.

2DiD (Design is Dead)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-11
Description

Lucid Group acquired the US-based strategic brand consultancy DiD to enhance its digital and healthcare services globally. The acquisition aims to strengthen Lucid's capabilities in addressing complex healthcare issues and expanding its market presence in the US.

zenopa.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Independent healthcare communications and data analytics firm offering integrated strategy, creative, and data-driven marketing for life sciences clients. Highly comparable to Lucid in scope (medical communications, omnichannel activation, AI-enabled insights) and customer base (top pharma and biotech), positioning it as a primary direct peer.

TypeDirect peer
Description

CD&R-backed global healthcare commercialisation platform offering medical communications, consulting, and patient solutions across the product lifecycle. Directly comparable as a PE-backed consolidator in the same healthcare communications and commercialisation space, with overlapping service lines (medical affairs, launch excellence, strategic consulting).

TypeDirect peer
Description

PE-backed (Bridgepoint) healthcare communications group offering medical communications, consulting, and creative services to pharma clients. Directly comparable business model and customer base, with similar focus on launch support and scientific storytelling for life sciences brands.

TypeBroad incumbent
Description

Large network of healthcare communications agencies under Publicis Groupe offering advertising, PR, medical communications, and data services. Comparable to Lucid's commercial communications and medical affairs capabilities but at significantly greater scale with broader geographic reach and bundled holding company offerings.

TypeBroad incumbent
Description

Network of healthcare-focused agencies under Omnicom providing advertising, branding, medical education, and consulting to pharma and biotech. Comparable service portfolio to Lucid with substantially larger scale, deeper media capabilities, and global procurement relationships with top pharma clients.

TypeBroad incumbent
Description

Specialised healthcare communications network under Interpublic Group offering medical communications, brand strategy, and DTC advertising for pharma. Comparable to Lucid in therapeutic area depth and launch support but with broader network reach and deeper resources across creative and media.

TypeBroad incumbent
Description

Global healthcare communications network under Havas offering creative, medical education, and patient engagement services. Comparable in serving pharma and biotech with launch and lifecycle communications, though larger and more diversified than Lucid's focused portfolio.

TypeBroad incumbent
Description

Global healthcare communications network under IPG/McCann offering advertising, consulting, and medical communications for pharma clients. Comparable in serving top pharma with launch and brand strategy work, though it operates as part of a broader holding company structure.

TypeEmerging player
Description

Clinical and commercial services organisation offering both CRO services and commercialisation/communications support for biopharma. Comparable in the commercial/launch support portion of its portfolio but with greater emphasis on clinical research and broader integrated offerings.

10ZS Associates
TypeEmerging player
Description

Global management consulting and professional services firm with significant pharma practice covering sales, marketing, and analytics strategy. Comparable to Lucid's strategy consulting and LCI analytics capabilities for life sciences clients, though more consulting-led than creative-led.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lucid Group

Healthcare Communications Consultingwearelucidgroup.com

Lucid Group is a London-headquartered healthcare communications consultancy serving pharmaceutical, biotech, MedTech, and consumer health clients with strategy consulting, medical communications, and AI-enabled analytics across UK and US offices.

What Lucid Group does

Lucid Group is a London-headquartered strategic healthcare communications consultancy founded in 2007, serving pharmaceutical, biotechnology, medical device, and consumer healthcare companies. The firm delivers an integrated portfolio spanning strategy consulting, scientific and medical communications, commercial communications, and digital/creative services, with approximately 500-600 specialists operating from four offices in the UK (London, Macclesfield, Manchester) and the US (Philadelphia). The company is privately held and backed by alternative asset manager Intermediate Capital Group (ICG), with founder Dennis O'Brien continuing as CEO and former Pfizer R&D leader Rod MacKenzie appointed Board Chair in 2026.

At the core of Lucid's offering is the proprietary Lucid Connected Intelligence (LCI) platform, which mines millions of patient healthcare interaction data points spanning diagnosis, prescription, procedure, demographic, and geographic information to support market definition, journey mapping, HCP behavior analysis, and campaign optimisation. AI-enabled solutions are positioned as 'woven in by design' across the asset lifecycle, supporting strategy refinement, content generation, and omnichannel activation. Lucid reports a 20+ year track record with 100+ product launches delivered across high-science therapeutic areas, with documented outcomes including 168% of sales target achievement for an oncology launch, 9x audience growth with doubled ROI to 5.6:1 for a multiple sclerosis brand, and 63% oncologist brand recognition within six months of launch.

Lucid monetises through project-based professional services engagements and retainer arrangements with enterprise life sciences clients, building bespoke teams per engagement. The firm has expanded through inorganic moves including the 2019 acquisition of HealthCare21, the 2021 acquisition of US-based DiD (strategic brand consultancy), and the 2023 acquisition of Synetic Life Sciences (life sciences management consulting). Lucid holds ISO 27001 certification (2025), EcoVadis Silver status placing it in the top 25% of rated companies, and United Nations Global Compact membership, signalling enterprise-grade security and ESG maturity valued by global pharma procurement.

Lucid Group firmographics

Firmographics
Name
Lucid Group
Legal name
Lucid Group Communications Limited
Website
https://wearelucidgroup.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Lucid Group is a London-headquartered healthcare communications consultancy serving pharmaceutical, biotech, MedTech, and consumer health clients with strategy consulting, medical communications, and AI-enabled analytics across UK and US offices.
Ownership category
akta.pro rank

Lucid Group industry classification

Industry
Product category
Healthcare Communications Consulting
NAICS
Advertising, Public Relations, and Related Services (5418), Management Consulting Services (54161), Marketing Consulting Services (541613)
SIC
Services-Management Consulting Services (8742)
akta.pro industry
PRIMARYMPAAADAD
Healthcare & Life Sciences PR
Media, Entertainment & Sports/Advertising, Marketing & PR Services/Public Relations & Communications Agencies

Keywords

  • Healthcare communications
  • Pharmaceutical consulting
  • Medical communications services
  • Life sciences strategy
  • Brand commercialisation consulting

Where Lucid Group is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices5 records

Markets served

Lucid Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Strategic Consulting Services: Strategy consulting engagements for life sciences including clinical development, medical affairs, asset commercialisation, and HCP/patient engagement
  2. Scientific and Medical Communications: Strategic scientific and medical communications services with deep scientific and therapy area expertise supporting Global and US markets
  3. Commercial Communications: Commercial communications services including omnichannel programmes, creative development, and brand strategy execution
  4. Digital and Creative Services: Digital and creative consultancy services integrated with strategic communications for end-to-end healthcare marketing solutions

Pricing tiers

ModelBillingPrice
Other—Project-based consulting engagements for life sciences organisations

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Lucid Group product offering

Product offering

Core offering

Lucid Group is a global healthcare communications consultancy that helps pharmaceutical, biotech, and life sciences companies translate scientific evidence into stakeholder belief and commercial outcomes across the asset lifecycle. Its portfolio includes Strategy Consulting, Scientific and Medical Communications, Commercial Communications, and proprietary analytics through the Lucid Connected Intelligence (LCI) platform, supported by AI-Powered Solutions and acquired capabilities from DiD Agency and Synetic Life Sciences.

Product overview

Lucid Group is a global strategic healthcare communications consultancy offering an integrated portfolio of services. The core offering comprises Strategy Consulting (strategic solutions for life sciences spanning clinical development, medical affairs, and commercialisation), Scientific and Medical Communications (translating scientific insight into impactful narratives), Commercial Communications (omnichannel programmes and creative development), and AI-Powered Solutions (AI-enabled tools woven throughout all services). The proprietary Lucid Connected Intelligence (LCI) platform serves as the analytics engine powering data-driven insights across the portfolio. The company has expanded through strategic acquisitions including DiD Agency (US-based strategic brand consultancy with customer-centric marketing expertise) and Synetic Life Sciences (life sciences management consulting for operating model design and implementation).

Differentiator

Problem solved

Functional benefit

Brands

  • Lucid Connected Intelligence (LCI): Proprietary business intelligence engine that mines patient healthcare interaction data for analytics and targeting
  • AI-Powered Solutions
  • DiD
  • Synetic Life Sciences
  • Lighthouse Medical Communications

Products and services

  • Strategy Consulting Strategic consulting services for life sciences organisations spanning clinical development, medical affairs, asset commercialisation, and HCP/patient engagement, using data- and science-based approaches to help clients set direction and transform ideas into action across the product lifecycle.
  • Scientific and Medical Communications Strategic scientific and medical communications services with deep therapy-area expertise supporting global and US markets, translating scientific insight into impactful strategies and compelling narratives that inspire behaviour change among HCPs and other stakeholders.
  • Commercial Communications Commercial communications services including omnichannel programmes, creative development, media planning and activation, and digital content designed to drive clinical change, champion early adopters, and grow brand awareness for healthcare clients.
  • Lucid Connected Intelligence (LCI) Proprietary advanced analytics platform that mines patient healthcare interaction data — including diagnosis, prescription, procedure, demographic, and geographic data — to identify patterns in patient populations, HCP behaviours, and market dynamics, enabling data-driven targeting, segmentation, and campaign optimisation for healthcare brands.
  • AI-Powered Solutions AI-enabled solutions integrated with human insight, therapeutic depth, and behaviour-change expertise to amplify insight, accelerate execution, sharpen strategy, and drive lasting impact across the asset lifecycle.
  • DiD Agency US-based strategic brand consultancy specialising in customer-centric marketing for life sciences, offering the 3-30/3-30 engagement framework for healthcare communications with expertise in market research, strategic insight development, and creative execution.
  • Synetic Life Sciences Management consulting firm dedicated to life sciences, offering operating model design and implementation, strategic process and capability development, and support for planning and execution across the asset lifecycle.

Quantifiable outcome

  • 168% of product sales target met within 6 months of launch for first systemic therapy in specialised oncology
  • +4 more outcomes

Companies that use Lucid Group

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles5 records

Lucid Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Lucid Group partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Synetic Life SciencescoreStrategic or Co-development Partner · 18 January 2023Lucid Group acquired Synetic Life Sciences, a management consulting firm dedicated to the life sciences industry. The acquisition provides clients with an end-to-end partnership across the development and commercialisation journey. Synetic supports clients with the design and implementation of operating models including building effective strategies, processes, capabilities, and organisational constructs.
  • DiD (Design is Dead)coreStrategic or Co-development Partner · 11 June 2021Lucid Group acquired the US-based strategic brand consultancy DiD to enhance its digital and healthcare services globally. The acquisition aims to strengthen Lucid's capabilities in addressing complex healthcare issues and expanding its market presence in the US.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Lucid Group competitors and assessment

Company assessment

Direct peers

  • Real Chemistry: Independent healthcare communications and data analytics firm offering integrated strategy, creative, and data-driven marketing for life sciences clients. Highly comparable to Lucid in scope (medical communications, omnichannel activation, AI-enabled insights) and customer base (top pharma and biotech), positioning it as a primary direct peer.
  • Inizio (formerly Ashfield): CD&R-backed global healthcare commercialisation platform offering medical communications, consulting, and patient solutions across the product lifecycle. Directly comparable as a PE-backed consolidator in the same healthcare communications and commercialisation space, with overlapping service lines (medical affairs, launch excellence, strategic consulting).
  • Fishawack Health: PE-backed (Bridgepoint) healthcare communications group offering medical communications, consulting, and creative services to pharma clients. Directly comparable business model and customer base, with similar focus on launch support and scientific storytelling for life sciences brands.

Broad incumbents

  • Publicis Health: Large network of healthcare communications agencies under Publicis Groupe offering advertising, PR, medical communications, and data services. Comparable to Lucid's commercial communications and medical affairs capabilities but at significantly greater scale with broader geographic reach and bundled holding company offerings.
  • Omnicom Health Group: Network of healthcare-focused agencies under Omnicom providing advertising, branding, medical education, and consulting to pharma and biotech. Comparable service portfolio to Lucid with substantially larger scale, deeper media capabilities, and global procurement relationships with top pharma clients.
  • IPG Health: Specialised healthcare communications network under Interpublic Group offering medical communications, brand strategy, and DTC advertising for pharma. Comparable to Lucid in therapeutic area depth and launch support but with broader network reach and deeper resources across creative and media.
  • Havas Health & You: Global healthcare communications network under Havas offering creative, medical education, and patient engagement services. Comparable in serving pharma and biotech with launch and lifecycle communications, though larger and more diversified than Lucid's focused portfolio.
  • McCann Health: Global healthcare communications network under IPG/McCann offering advertising, consulting, and medical communications for pharma clients. Comparable in serving top pharma with launch and brand strategy work, though it operates as part of a broader holding company structure.

Emerging players

  • Syneos Health (now private under Elliott/Veritas): Clinical and commercial services organisation offering both CRO services and commercialisation/communications support for biopharma. Comparable in the commercial/launch support portion of its portfolio but with greater emphasis on clinical research and broader integrated offerings.
  • ZS Associates: Global management consulting and professional services firm with significant pharma practice covering sales, marketing, and analytics strategy. Comparable to Lucid's strategy consulting and LCI analytics capabilities for life sciences clients, though more consulting-led than creative-led.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Lucid Group social profiles

Digital presence

Lucid Group compliance and trust

Trust signal

Compliance1 record

Lucid Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lucid Group leadership team

Management profile

Number of profiles

Profiles4 records

Lucid Group subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Lucid Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lucid Group M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lucid Group

What does Lucid Group do?

Lucid Group is a global healthcare communications consultancy that helps pharmaceutical, biotech, and life sciences companies translate scientific evidence into stakeholder belief and commercial outcomes across the asset lifecycle. Its portfolio includes Strategy Consulting, Scientific and Medical Communications, Commercial Communications, and proprietary analytics through the Lucid Connected Intelligence (LCI) platform, supported by AI-Powered Solutions and acquired capabilities from DiD Agency and Synetic Life Sciences.

Is Lucid Group a public or private company?

Lucid Group is a private company. It is classified as private equity controlled and is currently operating.

When was Lucid Group founded?

Lucid Group was founded in 2007. It employs 101 to 250 people.

Where is Lucid Group based?

Lucid Group is headquartered in London, United Kingdom, in the Europe region.

How does Lucid Group make money?

Four revenue lines are on record. Strategic Consulting Services are the primary driver. The others are scientific and Medical Communications, commercial Communications and digital and Creative Services.

Who are Lucid Group's main competitors?

Direct peers on record are Real Chemistry, Inizio (formerly Ashfield) and Fishawack Health. Broad incumbents are Publicis Health, Omnicom Health Group, IPG Health, Havas Health & You and McCann Health. Emerging players are Syneos Health (now private under Elliott/Veritas) and ZS Associates.

Does Lucid Group have an API?

No public API is recorded for Lucid Group.

What industry is Lucid Group in?

Lucid Group's product category is Healthcare Communications Consulting. Its primary akta.pro industry code is MPAAADAD, Healthcare & Life Sciences PR. Its NAICS code is 5418 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comLucid registers shares for resale to fulfill contractual obligations By Investing.comLucid Group Inc. filed a prospectus supplement with the Securities and Exchange Commission to register shares for resale in order to fulfill contractual obligations. The registration covers up to 55,000 shares of Series C Convertible Preferred Stock and approximately 75.7 million shares of Class A Common Stock held by Ayar Third Investment Company and SMB Holding Corporation, a subsidiary of Uber Technologies Inc. No new shares are being issued or sold by Lucid itself, and the existing holders face transfer restrictions until 2027.Third NewsLucid Group Files Resale Prospectus for Stock in Electric Vehicle IndustryLucid Group filed a resale prospectus supplement with the SEC to register up to 51 million shares of Class A Common Stock and approximately 24 million additional shares for resale by existing shareholders. The filing addresses contractual obligations to Ayar Third Investment Company, linked to Saudi Arabia's Public Investment Fund, and SMB Holding Corporation, a subsidiary of Uber Technologies. Transfer restrictions prevent these specific holders from selling their shares until April and October 2027 respectively.Electric Cars ReportLucid Reveals Midsize EV Platform, Atlas Drive Unit and Robotaxi VisionLucid Group unveiled its Midsize EV platform at an investor day in New York, introducing the next-generation Atlas electric drive unit and a robotaxi concept called Lunar, with plans to launch affordable premium EVs under $50,000 including the Cosmos and Earth SUVs. The company also finalized a deepened partnership with Uber to deploy autonomous vehicles based on the Midsize platform in robotaxi fleets. Lucid outlined a profitability roadmap focused on scaling Gravity production, improving manufacturing efficiency, reducing battery costs, and diversifying revenue through software services, platform licensing, and autonomous vehicle technologies.MarketScreenerLucid Group Expands California Retail Presence With 2 New StoresLucid Group, Inc. expanded its retail presence in California by opening two new stores. The company focuses on designing and manufacturing electric vehicles, including the luxury Lucid Air sedan, at its Arizona plant, with a network of service centers and mobile service vehicles.HomeLucid Group Makes History in Saudi Arabia as it Opens Country's First-Ever Car Manufacturing FacilityLucid Group officially opened its first international manufacturing facility, AMP-2, in King Abdullah Economic City, Saudi Arabia, marking the country's first-ever car manufacturing plant. The facility initially has an annual assembly capacity of 5,000 vehicles and supports a government agreement to purchase up to 100,000 Lucid Airs over ten years.